Weekly Enforcement Update: Inflated Claims Are a Key Theme
Though last week’s cases didn’t involve labs or lab testing, most were FCA-related issues including inflated claims.
Though last week’s cases didn’t involve labs or lab testing, most were FCA-related issues including inflated claims.
As we move further into 2023, COVID-19, add-on, and genetic tests will likely remain targets for federal regulators.
A new OIG Advisory Opinion sheds some light on how to properly structure these arrangements in a hospital inpatient setting.
Last week saw the usual False Claims Act and kickback-related charges, with the biggest action involving urine drug testing.
Most of last week’s healthcare-related actions involved telemedicine in some way, with the lone lab-related case centering on genetic testing.